Evidence map›Paper›PMID 25973288›Full record

ArticleJournal of clinical imaging science2015

Cross-sectional Imaging Features of Primary Retroperitoneal Tumors and Their Subsequent Treatment.

Turker Acar, Mustafa Harman, Serkan Guneyli, Kazim Gemici, Duran Efe, Ibrahim Guler, Melda Yildiz

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical imaging science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Impact of retroperitoneal tumors on the digestive tract (Review).Experimental and therapeutic medicine · 2022
    Review
  2. Solid Primary Retroperitoneal Masses in Adults: An Imaging Approach.The Indian journal of radiology & imaging · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Turker AcarDepartment of Radiology, Mevlana University School of Medicine, Konya, Turkey.
Mustafa HarmanDepartment of Radiology, Ege University School of Medicine, Izmir, Turkey.
Serkan GuneyliDepartment of Radiology, Bulent Ecevit University School of Medicine, Zonguldak, Turkey.
Kazim GemiciDepartment of General Surgery, Mevlana University School of Medicine, Konya, Turkey.
Duran EfeDepartment of Radiology, Mevlana University School of Medicine, Konya, Turkey.
Ibrahim GulerDepartment of Radiology, Konya Education and Research Hospital, Konya, Turkey.
Melda YildizDepartment of Radiology, Mevlana University School of Medicine, Konya, Turkey.
Mevlana University · TRBülent Ecevit University · TREge University · TRKonya Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Basically malignant tumors in the retroperitoneal region arise from a heterogeneous group of tissues: mesodermal, neurogenic, germ cell, and lymphoid. Although rare, benign tumors and cystic masses can be also encountered in retroperitoneal space. Developments in computed tomography (CT) and magnetic resonance imaging (MRI) have contributed to both diagnosis and staging of the retroperitoneal tumors. High spatial resolution and superiority in calcification make CT indispensable; on the other hand, MRI has a better soft-tissue contrast resolution which is essential for the assessment of vascular invasion and tissue characterization. The aim of this article is to review the CT and MRI features of retroperitoneal tumors and their subsequent management.

Indexed as

Computed tomographydiagnosismagnetic resonance imagingretroperitoneal neoplasmstreatment

Identifiers

PMID25973288
PMCPMC4421890
OpenAlexW2049000120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.